California's AB 824 law has important implications for branded and generics companies involved in settlement agreements. AB 824 presumes, for example, that "reverse payment" agreements are illegal.
Advanced analytics enable life sciences companies to optimize the trials, facilitating data-driven decisions that significantly reduce the time and financial burdens associated with drug development.
Expert Priyanka Gupta explains how intensified solutions for upstream and downstream processes can increase productivity by 4 times and reduce upfront investment by 50%.
First-in-human oncology trials are critical touchpoints in the development of novel cancer therapies, requiring precise scientific execution and a deeply patient-centric approach.
Gene therapies are expanding beyond rare diseases, but high costs hinder access. Discover how innovations in viral vector manufacturing could make these breakthroughs more affordable.
Financial stability is critical for trial sites, yet many sites grapple with substantial payment delays. To mitigate these challenges, it's imperative to reassess traditional payment practices,
ADCs have proven to be highly effective in cancer treatment, but their manufacturing poses challenges. Learn how a CDMO partner can help bring these treatments to patients safely and efficiently.
This website uses cookies to ensure you get the best experience on our website. Learn more
